Monte Rosa Therapeutics, Inc.
GLUE
$15.50
-$0.34-2.15%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.73M | 42.95M | 123.67M | 181.54M | 177.99M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.73M | 42.95M | 123.67M | 181.54M | 177.99M |
| Cost of Revenue | 162.36M | 145.41M | 133.70M | 130.57M | 121.44M |
| Gross Profit | -133.63M | -102.46M | -10.03M | 50.97M | 56.55M |
| SG&A Expenses | 48.22M | 45.82M | 44.18M | 42.46M | 41.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 210.58M | 191.23M | 177.88M | 173.03M | 163.03M |
| Operating Income | -181.85M | -148.28M | -54.21M | 8.51M | 14.96M |
| Income Before Tax | -163.97M | -131.88M | -39.72M | 21.95M | 28.42M |
| Income Tax Expenses | -2.86M | -1.87M | -1.10M | 1.01M | 4.26M |
| Earnings from Continuing Operations | -161.12 | -130.01 | -38.63 | 20.95 | 24.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -161.12M | -130.01M | -38.63M | 20.95M | 24.17M |
| EBIT | -181.85M | -148.28M | -54.21M | 8.51M | 14.96M |
| EBITDA | -173.73M | -139.94M | -45.85M | 16.84M | 23.30M |
| EPS Basic | -1.74 | -1.46 | -0.45 | 0.26 | 0.29 |
| Normalized Basic EPS | -1.11 | -0.93 | -0.29 | 0.17 | 0.22 |
| EPS Diluted | -1.75 | -1.47 | -0.45 | 0.25 | 0.29 |
| Normalized Diluted EPS | -1.11 | -0.93 | -0.29 | 0.16 | 0.21 |
| Average Basic Shares Outstanding | 369.31M | 350.02M | 332.28M | 328.85M | 328.47M |
| Average Diluted Shares Outstanding | 369.31M | 350.02M | 333.09M | 329.66M | 329.27M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |